Thomas de Vlaam, CEO and founder of Amylon Therapeutics, talks to Kari Bennett of EBD Group about winning the BIO-Europe® 2017 Startup Slam competition and what’s next in the clinic and in partnering for the young company. Amylon Therapeutics targets Central Nervous System (CNS) disorders through an ultra-genetics approach, focusing on rare genetic disorders that can serve as a possible gateway to more frequently occurring indications. He will receive a complimentary registration to BIO-Europe Spring® 2018 from EBD Group and the opportunity to enter a year-long no fee arrangement to become a Johnson & Johnson Innovation, JLINX community member. All contestants had to present their company and innovation—either a new therapeutic product or medical technology platform—in only three minutes to a floor of experienced investors and potential collaboration partners.
Get the latest news as it happens.